Please assess the completion status of the following clinical trial:

Trial Title: The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating females greater than or equal to (≥) 18 years old.~* In remission from demonstrated overt HE (Conn score 0 or 1).~* Have had one or more episodes of overt HE associated with cirrhosis within 6 months prior to screening visit (Day -7 to -1).~* Participant has a close family member or other personal contact who is familiar with the participant's HE and can provide continuing oversight to the participant and is willing to perform as caregiver for the participant during the conduct of the trial.~Exclusion Criteria:~* Participant has been diagnosed with human immunodeficiency virus (HIV) as determined by medical history.~* History of tuberculosis infection.~* Participant has been diagnosed with chronic respiratory insufficiency.~* Participant has been diagnosed with a current infection for which they are currently taking oral or parenteral antibiotics.~* Renal insufficiency requiring routine dialysis.~* Participant has an active spontaneous bacterial peritonitis(SBP) infection.~* Intestinal obstruction or inflammatory bowel disease.~* Participant has active malignancy within the last 5 years prior to screening visit, except basal cell carcinoma of the skin, or if female, in situ cervical carcinoma that has been surgically excised.~* Current gastrointestinal (GI) bleeding or has a history of a GI hemorrhage of sufficient severity to require hospitalization and a transfusion of ≥2 units of blood within 3 months prior to screening visit.~* Participant is anemic, as defined by a hemoglobin of less than (\<) 8 grams/deciliter (g/dL).~* Scheduled to receive a liver transplant within 1 month of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin 550 mg BID (Type: EXPERIMENTAL): Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
- Rifaximin 550 mg BID + Lactulose (Type: EXPERIMENTAL): Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).